| [1] Raguz S, Yague E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer, 2008, 99(3): 387–391. <\p>
[2] Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology, 2008, 81(4): 275–300. <\p>
[3] Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res, 1996, 56(13): 3087– 3090. <\p>
[4] Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res, 1998, 4(1): 1–6. <\p>
[5] Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res, 2000, 60(21): 6039– 6044. <\p>
[6] Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene, 1999, 18(14): 2335–2341. <\p>
[7] Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res, 2004, 10(13): 4420–4426. <\p>
[8] Li D, Kumaraswamy E, Harlan-Williams LM, Jensen RA. The role of BRCA1 and BRCA2 in prostate cancer. Front Biosci (Landmark Ed), 2013, 18(4): 1445–1459. <\p>
[9] Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol, 2000, 10(15): 886–895. <\p>
[10] Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer, 2012, 12(12): 801– 817. <\p>
[11] Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res, 1998, 58(6): 1120–1123. <\p>
[12] Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst, 2004, 96(22): 1659–1668. <\p>
[13] Esteller M, Silva JM, Dominguez G, Bonilla F, Matias- Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst, 2000, 92(7): 564–569. <\p>
[14] Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res, 2005, 65(19): 8961–8967. <\p>
[15] Tolomeo M, Simoni D. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Curr Med Chem Anticancer Agents, 2002, 2(3): 387–401. <\p>
[16] Jones PA. Cancer: death and methylation. Nature, 2001, 409(6817): 141–144. <\p>
[17] Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature, 2001, 409(6817): 207–211. <\p>
[18] Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn- Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene, 2001, 20(41): 5865–5877. <\p>
[19] Chaopatchayakul P, Jearanaikoon P, Yuenyao P, Limpaiboon T. Aberrant DNA methylation of apoptotic signaling |
